← Back to Search

Cancer Vaccine

GRT-C903 for Solid Tumors

Phase 1 & 2

Waitlist Available

Research Sponsored by Gritstone Oncology, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to approximately 4 years

Awards & highlights

Study Summary

This trial is testing a new cancer vaccine in combination with immune checkpoint blockade. The goal is to see if it is safe and works against various types of cancer.

Eligible Conditions

Shared Neoantigen-Positive Solid Tumors
Colorectal Cancer
Non-Small Cell Lung Cancer
Pancreatic Cancer
Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to approximately 4 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to approximately 4 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Identify the recommended Phase 2 dose (RP2D) of GRT-C903 and GRT-R904

Incidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs)

Objective Response Rate (ORR) in Phase 2 using RECIST v1.1

Secondary outcome measures

Clinical benefit rate (CBR) using RECIST v1.1

Duration of response (DOR) using RECIST v1.1

Measure the immune response to the neoantigens encoded by GRT-C903 and GRT-R904

+3 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: Phase 2Experimental Treatment4 Interventions

GRT-C903 GRT-R904 nivolumab ipilimumab Phase 2 for some patients includes a monthly or every two month treatment schedule

Group II: Phase 1Experimental Treatment4 Interventions

GRT-C903 GRT-R904 nivolumab ipilimumab

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

GRT-C903

2019

Completed Phase 2

~40

GRT-R904

2019

Completed Phase 2

~40

Nivolumab

FDA approved

Ipilimumab

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Gritstone Oncology, Inc.Lead Sponsor

5 Previous Clinical Trials

884 Total Patients Enrolled

Gritstone bio, Inc.Lead Sponsor

8 Previous Clinical Trials

1,308 Total Patients Enrolled

Bristol-Myers SquibbIndustry Sponsor

2,645 Previous Clinical Trials

4,130,960 Total Patients Enrolled

Media Library

GRT-C903 (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT03953235 — Phase 1 & 2

Solid Tumors Research Study Groups: Phase 2, Phase 1

Solid Tumors Clinical Trial 2023: GRT-C903 Highlights & Side Effects. Trial Name: NCT03953235 — Phase 1 & 2

GRT-C903 (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03953235 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the main maladies that GRT-C903 has been shown to improve?

"GRT-C903 can be used as a treatment for patients that have undergone anti-angiogenic therapy, those with malignant neoplasms, and patients with unresectable melanoma."

Answered by AI

What other data is available on GRT-C903?

"GRT-C903 was first studied in 2009 at Texas Children's Hospital. As of now, 360 studies have completed. There are 796 trials that are still recruiting patients, a majority of which are located in Phoenix, Arizona."

Answered by AI

How many research centers are coordinating this investigation?

"This clinical trial has 13 active sites, which are located in Phoenix, Nashville, Houston, and other cities."

Answered by AI

How many participants are being recruited for this trial?

"Yes, this is an ongoing trial that has currently enrolled 144 patients from 13 different sites. The study's original posting was on July 18th, 2019 with the latest update being September 10th of 2020."

Answered by AI

Are people still able to sign-up for this experiment?

"The trial, which was initially posted on July 18th 2019 and last updated September 10th 2020 according to clinicaltrials.gov, is presently looking for participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

2019. "A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03953235.